医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

JC Medical TAVI System Implanted First Time Outside China

2016年02月25日 PM09:00
このエントリーをはてなブックマークに追加


 

BURLINGAME, Calif.

JC Medical, Inc. announced today that it has successfully completed an implantation of its J-Valve bioprosthesis using the Ausper transapical delivery device in Vancouver, Canada. The J-Valve Ausper system represents the next generation transcatheter aortic valve implantation (TAVI) system and has been previously used in more than 100 patients in China. This operation is the first implantation of the J-Valve Ausper system outside of China.

The implantation was performed by Jian Ye, M.D., clinical professor of surgery and director of cardiac surgery research, and John Webb, M.D., director of interventional cardiology at St. Paul’s Hospital in Vancouver.

The patient suffered from debilitating heart failure symptoms due to severe aortic regurgitation and was considered to be at a high risk for open-heart aortic valve replacement surgery due to his condition.

“The J-Valve is a unique valve designed for both aortic regurgitation (non-calcified valves) and aortic stenosis (severe calcification),” Ye said. “Most TAVI devices are designed for aortic stenosis. Up to date, there are no transcatheter valves approved for the treatment of pure aortic regurgitation in North America. The J-Valve is relatively easier to implant compared with other valves, and provides true anatomical positioning. Furthermore, no rapid ventricular pacing is required during the entire procedure, which reduces myocardial stress. The clinical trial in China has showed good early outcomes.”

Aortic regurgitation, also known as aortic insufficiency, and aortic stenosis are both potentially life-threatening conditions related to the aortic valve that directs blood out of the heart to the rest of the body. An estimated 12 million people worldwide have heart valve diseases. Currently approved minimally invasive TAVI devices are only indicated for use in patients with aortic stenosis. The J-Valve Ausper TAVI System is designed to treat aortic regurgitation, as well as aortic stenosis.

“We are very pleased that our J-Valve system could help the patient in Canada,” said Ji Zhang, M.D., founder and CEO of JC Medical. “We thank the physician group who has recognized this unique clinical solution.”

JC Medical is currently pursuing market approval of the J-Valve Ausper TAVI System in China.

About JC Medical, Inc.
JC Medical, Inc. is a privately held, venture-backed developer and manufacturer of TAVI systems. The company’s first product is a next generation TAVI system that addresses an unmet need in patients with aortic regurgitation as well as aortic stenosis. The company has operational sites in Burlingame, Calif., and Suzhou, China.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005309/en/

CONTACT

Nobles Global Communications
Diana Soltesz, 818-618-5634
diana@noblesgc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定